GOT2 as a metabolic and immunologic target in pancreatic cancer (2025)

Compuscript LtdApr 20 2025

Unlike conventional approaches that often face resistance or poor efficacy, targeting GOT2 offers a multi-pronged strategy. Its activity is closely tied to the production of aspartate and α-ketoglutarate, vital for nucleotide and protein biosynthesis and ATP generation. These metabolic outputs are particularly essential for pancreatic cancer cells, which rely on a distinct, non-canonical glutamine metabolic route often driven by oncogenic KRAS mutations. Inhibiting GOT2 disrupts this pathway, leading to a collapse in redox equilibrium and accumulation of reactive oxygen species, thereby triggering cellular senescence and loss of proliferative capacity.

The enzyme's significance extends beyond metabolism. Recent discoveries have unveiled an unexpected nuclear function of GOT2, where it operates as a fatty acid transporter that activates PPARδ, a transcription factor involved in immune regulation. By promoting the expression of genes like PTGS2, CSF1, and REG3G, GOT2 fosters an immunosuppressive microenvironment, hindering T-cell infiltration and supporting tumor immune evasion. These dual functions position GOT2 as a linchpin at the intersection of metabolic programming and immune suppression, highlighting its appeal as a target for novel combination therapies.

Despite its critical role, pancreatic tumors exhibit adaptive resistance mechanisms. Some cancer cells circumvent GOT2 loss through macropinocytosis or by acquiring metabolites from cancer-associated fibroblasts, allowing them to replenish aspartate independently. Understanding and counteracting these resistance pathways is essential for optimizing GOT2-based treatments.

The pursuit of effective GOT2 inhibitors is ongoing, with promising early candidates like amino oxyacetate showing potential. Future research must refine these compounds and explore their integration with immunotherapies or redox-modulating treatments.

Source:

Journal reference:

Comments (0)

Expansion of mutant blood cells linked to worse cancer outcomes

New study questions poultry's health halo amid rising cancer risks

Lipid metabolism as a driver of therapy resistance in triple negative breast cancer

Yale study links childhood thyroid cancer risk to air and light pollution

Mediterranean diet lowers breast cancer risk by 13%, postmenopausal women benefit most

Medicare claims for genetic cancer tests face growing rejection rates

Can a plant-based diet help prevent breast cancer?

Major breakthrough could turn IV drugs into oral treatments for brain cancer and Alzheimer's

Quirky Comment Title

Post